| Aerpio Pharmaceuticals is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Co.'s main product candidate, AKB-9778, a small molecule inhibitor of the Tie2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. AKB-9778 works by inhibiting vascular endothelial protein tyrosine phosphatase, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. Co. has AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1 alpha). AKB-4924, now called GB004, is being developed for the treatment of inflammatory bowel disease. We show 16 historical shares outstanding datapoints in our ARPO shares outstanding history coverage, used to compute ARPO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARPO market cap history over the course of time is important for investors
interested in comparing ARPO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARPO versus a peer is one thing; comparing
ARPO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARPO can fluctuate over the course of history.
With this page we aim to empower investors researching ARPO by allowing them to research the ARPO market cap history.